A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Portage Biotech
ImmunityBio, Inc.
M.D. Anderson Cancer Center
NSABP Foundation Inc
NKGen Biotech, Inc.
University of Southern California
Southwest Hospital, China
University of Pittsburgh
Case Comprehensive Cancer Center
University of Louisville
Merrimack Pharmaceuticals
Medical College of Wisconsin
University of Southern California